Biography
Jean Abraham is Professor of Precision Breast Cancer Medicine and an Honorary Consultant in Medical Oncology at the University of Cambridge. She directs the Precision Breast Cancer Institute and co-leads the Integrated Cancer Medicine theme and the Breast Programme in the Cancer Research UK Cambridge Centre. Jean is deputy theme lead for Cancer at the Cambridge NIHR Biomedical Research Campus. She is Chief Investigator of eight national/regional trials. She is a member of the National Clinical Studies Group for Breast Cancer and has advised NICE on breast cancer therapeutics and the House of Commons Select Committee on Genomics. She completed her undergraduate training in Pharmacology and in Medicine at the University of Liverpool. She was awarded a Cancer Research UK National Clinical Training Fellowship and completed her PhD at the University of Cambridge.
Research
My research aims are as follows:
i. develop innovative clinical trials in high risk and hereditary early stage breast cancers;
ii. use multi-modal data integration to develop predictive and prognostic tools to provide individualised treatment strategies for breast cancer patients to improve clinical outcomes.
Publications
• Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra A, Qian W, Vallier AL, Hardy RM, Chan S, Hickish T, Tripathi D, Venkitaraman R, Persic M, Aslam S, Glassman D, Raj S, Borley A, Braybrooke JP, Sutherland S, Staples E, Scott LC, Davies M, Palmer CA, Moody M, Churn MJ, Newby JC, Mukesh MB, Chakrabarti A, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Tischkowitz M, Provenzano E, Earl HM. The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07384-2. Epub ahead of print. PMID: 38588696.
• Dorling L, …Pharoah PDP, Abraham JE. Genetic markers predictive of breast cancer risk may also predict reduced incidence of chemotherapy-induced neutropenia. Accepted by Plos One June 2016.
• Abraham JE, Hiller L, Dorling L, Vallier AL, Dunn J, Bowden S, et al. A nested cohort study of over 6000 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine. 2015; 13:306.
• Helena M Earl, Louise Hiller, Janet A Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Jean Abraham,….Larry Hayward, for the ARTemis Investigators. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16(6):656-66.
• Guo Q, Schmidt M. K, Kraft P, Canisius S, Chen C, Khan S, ….Abraham JE …et al. Identification of novel genetic markers of breast cancer survival. J Natl Cancer Inst. 2015 Apr 18;107(5).
• Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL, et al. Replication of Genetic Polymorphisms Reported to be Associated with Taxane-Related Sensory Neuropathy in Early Breast Cancer Patients treated with Paclitaxel. Clin Cancer Res 2014;1;20(9):2466-75
• Earl HM, Vallier A-L, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, et al. Neo-adjuvant sequential epirubicin, cyclophosphamide, and paclitaxel, with or without gemcitabine, for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2 x 2 factorial randomised phase 3 trial. Lancet Oncol 2014; 15(2): 201-212.
